perindopril has been researched along with Coronary Disease in 58 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.45) | 18.7374 |
| 1990's | 5 (8.62) | 18.2507 |
| 2000's | 44 (75.86) | 29.6817 |
| 2010's | 6 (10.34) | 24.3611 |
| 2020's | 1 (1.72) | 2.80 |
| Authors | Studies |
|---|---|
| Barbashina, TA; Gavriljuk, EV; Mal, GS; Pribylov, CA; Pribylov, VS; Pribylova, NN; Yakovleva, MV | 1 |
| Rickenbacher, P | 1 |
| Gapon, LI; Kolesnikova, SN; Musikhina, NA; Petelina, TI; Utesheva, AB | 1 |
| Dinicolantonio, JJ; Lavie, CJ; O'Keefe, JH | 1 |
| Blomster, JI; Chalmers, J; Chow, CK; Harrap, S; Hillis, GS; Li, Q; Mancia, G; Neal, B; Patel, A; Poulter, N; Williams, B; Woodward, M; Zoungas, S | 1 |
| Mikhaĭlova, NV; Morozova, TE; Vartanova, OA | 1 |
| Maciejewski, P; Niessen, LW; Orlewska, E; Redekop, WK; Rutten, FF | 1 |
| Chang, CL; Dahlof, B; Mastorantonakis, S; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Krzesinski, JM; Scheen, AJ | 1 |
| Campbell, NR; Dahlöf, B; Dobson, JE; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Anderson, C; Arima, H; Chalmers, J; Liu, L; Macmahon, S; Neal, B; Omae, T; Rodgers, A; Tzourio, C; Woodward, M | 1 |
| Consuegra-Sanchez, L; Kaski, JC | 1 |
| Bots, ML; Grobbee, DE; Lüscher, TF; Remme, WJ | 1 |
| White, HD | 1 |
| Fox, KM | 1 |
| Hackam, DG | 1 |
| Zeiher, A | 1 |
| Clark, AL; Cleland, JG; Coletta, AP; Freemantle, N; Loh, H; Memon, A | 1 |
| Owen, OG | 1 |
| Boos, C | 1 |
| Stoschitzky, K | 1 |
| Becker, KL; Burman, KD; Kwaku, M; Mannan, M | 1 |
| Brophy, JM | 1 |
| Fuller, JA | 1 |
| Mackay, JA | 1 |
| Haghfelt, A; Haghfelt, T | 1 |
| Sica, DA | 1 |
| Algert, C; Bath, P; Chapman, N; Neal, B | 1 |
| Liebson, PR | 1 |
| Chalmers, J; Chapman, N; Colman, S; Lee, A; Liu, LS; MacMahon, S; Rodgers, A; Woodward, M | 1 |
| Keltai, M | 1 |
| Böhm, M | 1 |
| Cockcroft, JR | 1 |
| Füessl, HS | 1 |
| Ambrosio, G; Chiariello, M; Ferrari, R | 1 |
| Bernocchi, P; Bettini, A; Ceconi, C; Ferrari, R; Gimbatti, OJ; Golcea, SS; Papa, K | 1 |
| Anderson, C; Arima, H; Bousser, MG; Butcher, K; Chalmers, J; Lees, KR; MacMahon, S; Omae, T; Reid, JL; Tzourio, C; Woodward, M | 1 |
| Baba, S; Hosozawa, KI; Ikeda, K; Iwasaki, Y; Kashihara, H; Tamura, M | 1 |
| Bertrand, M; Briggs, A; Deckers, J; Ferrari, R; Fox, K; Hall, A; Mihaylova, B; Remme, WJ; Sculpher, M; Simoons, M; Wolstenholme, J | 1 |
| Bertrand, M; Blann, A; Ceconi, C; Cokkinos, D; Ferrari, R; Fox, KM; Kluft, C; Parrinello, G; Remme, WJ; Simoons, ML | 1 |
| Campbell, DJ | 1 |
| Antoniades, C; Kourtellaris, P; Papageorgiou, N; Siasos, G; Stefanadi, E; Stefanadis, C; Tentolouris, C; Tousoulis, D; Vasiliadou, C | 1 |
| Rahn, KH | 1 |
| Yan, XW | 1 |
| Bryszewska, M; Buczyński, A; Kedziora, J; Koter, M; Leyko, W; Piasecka, A; Tkaczewski, W | 1 |
| Bertrand, ME; Ferrari, R; Fox, KM; Henderson, JR; Remme, WJ; Simoons, ML | 1 |
| Bots, ML; de Feyter, PJ; de Maat, MP; Deckers, JW; Fox, KM; Grobbee, DE; Kluft, C; Remme, WJ; Simoons, ML; Vos, J | 1 |
| Aoki, M; Higaki, J; Matsumoto, K; Moriguchi, A; Morishita, R; Nakamura, T; Ogihara, T; Sakonjo, H; Tomita, N | 1 |
| Fox, KM; Gomma, AH | 1 |
| Beevers, G; Caulfield, M; Collins, R; Dahlöf, B; Kjeldsen, SE; McInnes, GT; Mehlsen, J; Nieminen, M; O'Brien, E; Ostergren, J; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Horiuchi, M; Kobayashi, K; Morishita, T; Nakashima, Y; Okuda, H; Shimokawa, H; Suda, O; Tasaki, H; Tsuda, Y; Tsutsui, M; Yanagihara, N | 1 |
| Mendelsohn, FA; Ohishi, M; Zhuo, JL | 1 |
| Bel, KJ; de Graeff, PA; de Langen, CD; Tobé, TJ; van Gilst, WH; van Wijngaarden, J; Weersink, EG; Wesseling, H | 1 |
| Boissel, JP; Chifflet, R; Girard, P; Leizorovicz, A; Lievre, M; Nony, P | 1 |
| Chardigny, JM; Diebold, H; Moreau, D; Rochette, L | 1 |
| Belichard, P; Bril, A; Devissaguet, M; Ribuot, C; Rochette, L | 1 |
10 review(s) available for perindopril and Coronary Disease
| Article | Year |
|---|---|
[Heart failure with "mid-range" ejection fraction: a new clinical entity?]
Topics: Aged; Aminobutyrates; Benzimidazoles; Biomarkers; Biphenyl Compounds; Comorbidity; Coronary Disease; Drug Combinations; Drug Therapy, Combination; Evidence-Based Medicine; Heart Failure; Humans; Natriuretic Peptides; Perindopril; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Spironolactone; Stroke Volume; Survival Rate; Syndrome; Tetrazoles; Valsartan | 2018 |
Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Cardiovascular System; Coronary Disease; Heart Failure; Humans; Hypertension; Myocardial Infarction; Perindopril; Ramipril | 2013 |
Blocking the renin-angiotensin-aldosterone system or lowering the blood pressure: does EUROPA help?
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Controlled Clinical Trials as Topic; Coronary Disease; Heart Diseases; Humans; Perindopril; Renin-Angiotensin System | 2003 |
EUROPA: has anything new been learned with angiotensin-converting enzyme inhibitors?
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Coronary Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Perindopril; Randomized Controlled Trials as Topic; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2004 |
[Preventive therapy with ACE inhibitors for coronary patients].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Clinical Trials as Topic; Coronary Disease; Death, Sudden, Cardiac; Enalapril; Humans; Indoles; Lisinopril; Myocardial Infarction; Perindopril; Ramipril; Treatment Outcome | 2004 |
Perindopril: the reasonable choice in patients with coronary artery disease.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aorta; Coronary Disease; Humans; Hypertension; Perindopril; Vascular Resistance | 2005 |
[Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI].
Topics: Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Coronary Disease; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Perindopril; Randomized Controlled Trials as Topic; Risk Factors; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Remodeling | 2005 |
A review of Perindopril in the reduction of cardiovascular events.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Coronary Disease; Drug Therapy, Combination; Humans; Hypertension; Perindopril; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Treatment Outcome | 2006 |
EUROPA substudies, confirmation of pathophysiological concepts. European trial on reduction of cardiac events with perindopril in stable coronary artery disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Coronary Angiography; Coronary Disease; Coronary Vessels; Endothelium, Vascular; Humans; Indoles; Perindopril; Prognosis; Treatment Outcome; Ultrasonography, Interventional | 1998 |
Relative efficacy of angiotensin converting enzyme inhibitors on mortality of patients with congestive heart failure: implications of randomized trials and role of the aetiology (ischaemic or non-ischaemic) of heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Coronary Disease; Enalapril; Follow-Up Studies; Heart Failure; Humans; Indoles; Meta-Analysis as Topic; Perindopril; Survival Rate | 1992 |
17 trial(s) available for perindopril and Coronary Disease
| Article | Year |
|---|---|
[Cerebral blood flow and endothelial functional activity in patients with coronary heart disease and arterial hypertension during therapy with ivabradine in combination with perindopril].
Topics: Benzazepines; Blood Flow Velocity; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cardiovascular Agents; Cerebrovascular Circulation; Coronary Disease; Drug Combinations; Electrocardiography; Endothelium, Vascular; Female; Heart Rate; Humans; Hypertension; Ivabradine; Male; Metoprolol; Middle Aged; Perindopril; Research Design; Treatment Outcome; Ultrasonography, Doppler | 2012 |
The relationship between alcohol consumption and vascular complications and mortality in individuals with type 2 diabetes.
Topics: Aged; Alcohol Drinking; Antihypertensive Agents; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Retinopathy; Drug Combinations; Female; Gliclazide; Humans; Hypertension; Hypoglycemic Agents; Indapamide; Male; Myocardial Infarction; Perindopril; Retrospective Studies; Risk Reduction Behavior; Stroke | 2014 |
Coronary heart disease benefits from blood pressure and lipid-lowering.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Blood Pressure; Coronary Disease; Heptanoic Acids; Humans; Hypertension; Perindopril; Pyrroles; Risk Factors; Risk Reduction Behavior; Sodium Chloride Symporter Inhibitors | 2009 |
Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial).
Topics: Aged; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Coronary Disease; Europe; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Perindopril; Proportional Hazards Models; Treatment Outcome | 2009 |
Perindopril-based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial.
Topics: Aged; Antihypertensive Agents; Asian People; Blood Pressure; Cerebrovascular Disorders; Coronary Disease; Double-Blind Method; Female; Heart Failure; Humans; Male; Middle Aged; Perindopril; Risk Factors; Stroke; Vascular Diseases; White People | 2010 |
PERindopril-Function of the Endothelium in Coronary Artery Disease Trial: the PERFECT study--sub study of EUROPA: rationale and design.
Topics: Angiotensin-Converting Enzyme Inhibitors; Brachial Artery; Coronary Disease; Double-Blind Method; Endothelium, Vascular; Follow-Up Studies; Humans; Perindopril; Treatment Outcome; Ultrasonography; Vasoconstriction; Vasodilation | 2002 |
Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cerebrovascular Disorders; Coronary Disease; Death, Sudden, Cardiac; Female; Heart Failure; Humans; Hypertension; Male; Middle Aged; Perindopril; Risk Factors; Treatment Outcome | 2003 |
Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Cause of Death; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heart Arrest; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Perindopril; Treatment Outcome | 2003 |
EUROPA: has anything new been learned with angiotensin-converting enzyme inhibitors?
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Coronary Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Perindopril; Randomized Controlled Trials as Topic; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2004 |
Perindopril-based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region.
Topics: Age Distribution; Aged; Angiotensin-Converting Enzyme Inhibitors; Asia; Australia; Blood Pressure; Coronary Disease; Europe; Female; Humans; Hypertension; Ischemic Attack, Transient; Male; Middle Aged; Perindopril; Proportional Hazards Models; Risk Factors; Sex Distribution; Stroke | 2004 |
Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Cardiovascular Diseases; Coronary Disease; Cost-Benefit Analysis; Drug Costs; Europe; Female; Health Care Costs; Hospitalization; Humans; Length of Stay; Male; Middle Aged; Perindopril; Quality-Adjusted Life Years; Risk Assessment | 2007 |
ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT.
Topics: Aged; Analysis of Variance; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Apoptosis; Biomarkers; Bradykinin; Cells, Cultured; Coronary Disease; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Humans; Male; Microscopy, Fluorescence; Middle Aged; Nitric Oxide; Nitric Oxide Synthase Type III; Perindopril; Proportional Hazards Models; Tumor Necrosis Factor-alpha; von Willebrand Factor | 2007 |
Effects of irbesartan and perindopril on forearm reactive hyperemia and inflammatory process, in normotensive patients with coronary artery disease.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Flow Velocity; Coronary Disease; E-Selectin; Enzyme-Linked Immunosorbent Assay; Female; Forearm; Humans; Hyperemia; Inflammation; Inflammation Mediators; Intercellular Adhesion Molecule-1; Irbesartan; Lipids; Male; Middle Aged; Perindopril; Tetrazoles; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2008 |
[The study on the tolerability of perindopril in patients with stable coronary heart disease].
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Coronary Disease; Female; Humans; Male; Middle Aged; Perindopril | 2007 |
The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA).
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Coronary Disease; Double-Blind Method; Europe; Female; Follow-Up Studies; Humans; Indoles; Male; Middle Aged; Patient Selection; Perindopril; Prognosis; Survival Rate; Treatment Outcome | 1998 |
EUROPA substudies, confirmation of pathophysiological concepts. European trial on reduction of cardiac events with perindopril in stable coronary artery disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Coronary Angiography; Coronary Disease; Coronary Vessels; Endothelium, Vascular; Humans; Indoles; Perindopril; Prognosis; Treatment Outcome; Ultrasonography, Interventional | 1998 |
Long-term treatment with perindopril ameliorates dobutamine-induced myocardial ischemia in patients with coronary artery disease.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Bradykinin; Coronary Disease; Dobutamine; Double-Blind Method; Electrocardiography; Female; Hemodynamics; Humans; Male; Middle Aged; Myocardial Ischemia; Peptidyl-Dipeptidase A; Perindopril; Sympathomimetics; Time Factors | 2002 |
33 other study(ies) available for perindopril and Coronary Disease
| Article | Year |
|---|---|
[Vasoprotective effects hypotensive therapy in patients with coronary heart disease combined with chronic kidney disease stage 2-3 after coronary stenting].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Coronary Disease; Drug Combinations; Humans; Hypertension; Perindopril; Pulse Wave Analysis; Renal Insufficiency, Chronic | 2021 |
[Possibilities of correction of coronary and myocardial reserves in patients with ischemic heart disease by Angiotensin converting enzyme inhibitor perindopril].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Coronary Disease; Endothelium, Vascular; Female; Humans; Male; Middle Aged; Myocardial Infarction; Perindopril; Russia; Severity of Illness Index; Ventricular Dysfunction, Left | 2008 |
Costs and effects of secondary prevention with perindopril in stable coronary heart disease in Poland: an analysis of the EUROPA study including 1251 Polish patients.
Topics: Angiotensin-Converting Enzyme Inhibitors; Coronary Disease; Cost-Benefit Analysis; Decision Trees; Female; Humans; Life Expectancy; Male; Middle Aged; Monte Carlo Method; Perindopril; Poland; Randomized Controlled Trials as Topic; Retrospective Studies; Risk; Secondary Prevention | 2008 |
[Fixed combination perindopril-amlodipine (Coveram) in the treatment of hypertension and coronary heart disease].
Topics: Administration, Oral; Amlodipine; Antihypertensive Agents; Coronary Disease; Drug Combinations; Humans; Hypertension; Perindopril; Treatment Outcome | 2009 |
PERTINENT (a substudy of the EUROPA trial): a persistent legacy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Coronary Disease; Endothelium, Vascular; Female; Humans; Male; Perindopril | 2012 |
Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors?
Topics: Adolescent; Adult; Angiotensin-Converting Enzyme Inhibitors; Coronary Disease; Follow-Up Studies; Humans; Myocardial Infarction; Perindopril; Ramipril; Randomized Controlled Trials as Topic; Research Design; Stroke; Treatment Outcome | 2003 |
ACE inhibition in stable coronary artery disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Coronary Disease; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Perindopril; Randomized Controlled Trials as Topic | 2003 |
[Coronary heart disease patient with no ischemic symptoms. Does he still profit from an ACE inhibitor?].
Topics: Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Perindopril; Risk; Survival Rate; Treatment Outcome | 2003 |
["Using chance, despite high NNT"].
Topics: Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Humans; Perindopril; Ramipril; Survival Rate | 2003 |
Clinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEM.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Azetidines; Benzimidazoles; Benzylamines; Biphenyl Compounds; Coronary Disease; Europe; Heart Failure; Humans; Natriuretic Peptide, Brain; Perindopril; Prodrugs; Randomized Controlled Trials as Topic; Tetrazoles | 2003 |
EUROPA shows role for ACE inhibition in low-risk CHD.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Coronary Disease; Female; Heart Failure; Humans; Male; Middle Aged; Perindopril; Tetrazoles; Treatment Outcome | 2003 |
The EUROPA trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Coronary Disease; Echocardiography; Humans; Perindopril; Ramipril; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome; Ventricular Dysfunction, Left | 2003 |
The EUROPA trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Coronary Disease; Heart Diseases; Humans; Perindopril; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
The EUROPA trial.
Topics: Age Factors; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Coronary Disease; Heart Diseases; Humans; Patient Selection; Perindopril; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
The EUROPA trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Coronary Disease; Drug Costs; Humans; Myocardial Infarction; Perindopril; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
Combine EUROPA and HOPE.
Topics: Angiotensin-Converting Enzyme Inhibitors; Coronary Disease; Heart Diseases; Humans; Meta-Analysis as Topic; Perindopril; Ramipril; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
[Angiotensin-converting enzyme inhibitors and chronic ischemic heart disease--new indications?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Coronary Disease; Female; Humans; International Cooperation; Male; Middle Aged; Myocardial Ischemia; Perindopril; Practice Guidelines as Topic; Randomized Controlled Trials as Topic | 2004 |
Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Australia; Blood Platelets; Cell Size; Cerebrovascular Disorders; China; Comorbidity; Coronary Disease; Diuretics; Female; Follow-Up Studies; Humans; Incidence; Ischemic Attack, Transient; Japan; Male; Middle Aged; Multicenter Studies as Topic; New Zealand; Perindopril; Predictive Value of Tests; Randomized Controlled Trials as Topic; Risk Assessment; Secondary Prevention; Stroke; Sweden | 2004 |
VALIANT and EUROPA.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Cardiovascular Diseases; Coronary Disease; Double-Blind Method; Heart Failure; Humans; Multicenter Studies as Topic; Myocardial Infarction; Perindopril; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
[ACE-inhibitor effects on the stabilization of coronary heart disease. EUROPA study].
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Coronary Disease; Female; Heart Arrest; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Perindopril; Randomized Controlled Trials as Topic; Treatment Outcome | 2004 |
[Antihypertensive therapy: campaign of the giants].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Coronary Disease; Drug Therapy, Combination; Humans; Hypertension; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Perindopril; Randomized Controlled Trials as Topic; Survival Analysis | 2005 |
[The long way of angiotensin-converting enzyme inhibitors in the fight against cardiovascular diseases].
Topics: Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Disease; Heart Failure; Humans; Myocardial Infarction; Perindopril; Randomized Controlled Trials as Topic; Time Factors; Ventricular Remodeling | 2005 |
Prior events predict cerebrovascular and coronary outcomes in the PROGRESS trial.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Brain Ischemia; Cerebral Hemorrhage; Coronary Disease; Female; Humans; Male; Middle Aged; Perindopril; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Risk Reduction Behavior; Stroke; Vascular Diseases | 2006 |
Concurrent dolichoectasia of basilar and coronary arteries.
Topics: Age of Onset; Aged; Aged, 80 and over; Antihypertensive Agents; Basilar Artery; Celiprolol; Coronary Disease; Coronary Vessels; Dilatation, Pathologic; Female; Genetic Predisposition to Disease; Humans; Hypertension; Indapamide; Male; Middle Aged; Perindopril; Stroke | 2006 |
[Treating essential hypertension. Are beta blockers still first choice?].
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Coronary Disease; Drug Therapy, Combination; Humans; Hypertension; Multicenter Studies as Topic; Myocardial Infarction; Outcome Assessment, Health Care; Perindopril; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Stroke | 2007 |
Effect of perindopril therapy on fluidity and potential of erythrocyte membrane from individuals with coronary heart disease.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Coronary Disease; Erythrocyte Membrane; Humans; Indoles; Male; Membrane Fluidity; Membrane Potentials; Middle Aged; Perindopril | 1997 |
Inhibition of neointima by angiotensin-converting enzyme inhibitor in porcine coronary artery balloon-injury model.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blotting, Northern; Bradykinin; Catheterization; Coronary Disease; Coronary Vessels; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation; Hepatocyte Growth Factor; Male; NG-Nitroarginine Methyl Ester; Perindopril; RNA, Messenger; Swine; Swine, Miniature; Tunica Intima; Vasodilation | 2001 |
The EUROPA trial: design, baseline demography and status of the substudies.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Coronary Disease; Diabetes Complications; Double-Blind Method; Europe; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multicenter Studies as Topic; Perindopril; Randomized Controlled Trials as Topic | 2001 |
Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Benzothiadiazines; Coronary Disease; Diuretics; Humans; Hypertension; Myocardial Infarction; Perindopril; Randomized Controlled Trials as Topic; Sodium Chloride Symporter Inhibitors | 2001 |
Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Autoradiography; Coronary Disease; Endothelium, Vascular; Female; Gene Expression; Humans; Immunohistochemistry; Male; Middle Aged; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Peptidyl-Dipeptidase A; Perindopril; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin | 2002 |
Effects of early angiotensin-converting enzyme inhibition in a pig model of myocardial ischemia and reperfusion.
Topics: 6-Ketoprostaglandin F1 alpha; Angiotensin-Converting Enzyme Inhibitors; Animals; Catecholamines; Coronary Disease; Creatine Kinase; Disease Models, Animal; Hemodynamics; Indoles; Male; Myocardial Reperfusion Injury; Perindopril; Random Allocation; Renin; Swine; Time Factors | 1992 |
[Direct cardiac effects of angiotensins I and II and 2 converting enzyme inhibitors (captopril and perindopril). Indirect demonstration of a converting enzyme in the rat heart].
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Captopril; Coronary Circulation; Coronary Disease; Heart; Heart Rate; Indoles; Male; Myocardium; Peptidyl-Dipeptidase A; Perindopril; Rats; Rats, Inbred SHR; Rats, Inbred Strains; Saralasin | 1988 |
Protective effect of angiotensin converting enzyme inhibitors (CEI): captopril and perindopril on vulnerability to ventricular fibrillation during myocardial ischemia and reperfusion in rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Coronary Circulation; Coronary Disease; Heart Rate; In Vitro Techniques; Indoles; Male; Norepinephrine; Perindopril; Rats; Ventricular Fibrillation | 1987 |